SYNAPTICS Inc (SYNA) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 16, 2026
Summary
SYNAPTICS’s revenue went from $1.7B in fiscal 2017 to $1.2B in fiscal 2026, a decline of about 3.9% a year.
Net income in fiscal 2026 was -$491M, a net margin of -41.0%; the best year in this period was 2022 with $258M.
Over the twelve months to September 26, 2026, revenue was $1.2B and net income -$488M.
Free cash flow was $101M in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count rose 9% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $959M | $1.4B | $1.7B | $1.3B | $1.3B | $1.5B | $1.6B | $1.7B |
| Gross profit | $551M | $535M | $480M | $440M | $716M | $943M | $611M | $543M | $497M | $480M | $524M |
| Operating income | -$57M | -$67M | -$94M | -$102M | $154M | $350M | $147M | $69M | -$6M | -$62M | $65M |
| Net income | -$488M | -$491M | -$48M | $126M | $74M | $258M | $80M | $119M | -$23M | -$124M | $49M |
| EPS (diluted) | $-12.54 | $-12.62 | $-1.22 | $3.16 | $1.83 | $0.00 | $2.08 | $3.41 | $-0.66 | $-3.63 | $1.37 |
| R&D | $378M | $382M | $347M | $336M | $351M | $367M | $313M | $302M | $343M | $363M | $292M |
| Revenue growth | — | +11.4% | +12.0% | −29.2% | −22.1% | +29.9% | +0.4% | −9.4% | −9.7% | −5.1% | +3.1% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $104M | $149M | $142M | $136M | $332M | $463M | $319M | $222M | $154M | $145M | $153M |
| Capital spending | -$39M | -$48M | -$26M | -$34M | -$34M | -$31M | -$21M | -$16M | -$24M | -$34M | -$31M |
| Free cash flow | $65M | $101M | $116M | $102M | $297M | $432M | $298M | $206M | $130M | $111M | $122M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $86M | $93M | $128M | $0 | $184M | $0 | $0 | $30M | $118M | $94M | $88M |
| Stock-based pay | $150M | $149M | $113M | $119M | $122M | $101M | $66M | $49M | $59M | $71M | $62M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $442M | $452M | $877M | $934M | $876M | $836M | $763M | $328M | $301M | $368M |
| Debt | — | $877M | $883M | $1.0B | $1.0B | $1.1B | $915M | $121M | $28M | — | $217M |
| Equity | — | $930M | $1.4B | $1.5B | $1.2B | $1.3B | $967M | $819M | $656M | $729M | $740M |
| Total assets | — | $2.1B | $2.6B | $2.8B | $2.6B | $2.9B | $2.2B | $1.7B | $1.4B | $1.5B | $1.3B |
| Shares (diluted) | 39M | 39M | 39M | 40M | 40M | 41M | 38M | 35M | 35M | 34M | 36M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 46.0% | 44.7% | 44.7% | 45.8% | 52.8% | 54.2% | 45.6% | 40.7% | 33.8% | 29.4% | 30.5% |
| Operating margin | -4.7% | -5.6% | -8.8% | -10.6% | 11.4% | 20.1% | 11.0% | 5.2% | -0.4% | -3.8% | 3.8% |
| Net margin | -40.7% | -41.0% | -4.5% | 13.1% | 5.4% | 14.8% | 5.9% | 8.9% | -1.6% | -7.6% | 2.8% |
| FCF margin | 5.4% | 8.5% | 10.8% | 10.6% | 21.9% | 24.8% | 22.2% | 15.4% | 8.9% | 6.8% | 7.1% |
| ROIC | — | -2.9% | -3.3% | -3.2% | 3.9% | 12.0% | 5.8% | 5.5% | -0.7% | -6.7% | 5.4% |
| ROE | — | -52.8% | -3.4% | 8.6% | 5.9% | 20.3% | 8.2% | 14.5% | -3.5% | -17.0% | 6.6% |
Frequently asked questions
What is SYNAPTICS’s annual revenue?
$1.2B in fiscal 2026 and $1.2B over the twelve months to September 26, 2026.
How much profit does SYNAPTICS make?
Net income was -$491M in fiscal 2026 (net margin -41.0%).
Is SYNAPTICS’s revenue growing?
Yes: revenue rose 11.4% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.